Proactive Investors - Run By Investors For Investors

Amryt Pharma expands exclusive licence agreement for Lojuxta

Rory Nealon, chief operating officer at Amryt Pharma PLC (LON:AMYT), tells Proactive's Andrew Scott they've signed an agreement with Aegerion Pharmaceuticals Inc to significantly expand their exclusive licence agreement for Lojuxta into Russia and the Commonwealth of Independent States, as well as the non-EU Balkan States.

Nealon says there could be up to 450 additional patients in the countries covered by the agreement who could benefit from Lojuxta - which treats a rare life-threatening disorder that causes abnormally high levels of "bad" cholesterol.

 
View full AMYT profile View Profile

Amryt Pharma PLC Timeline

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use